UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 158

Sortiert nach

Platinum Resistance: The Role of DNA Repair Pathways

Clinical cancer research, 2008-03, Vol.14 (5), p.1291-1295

2008

Link zum Volltext

Verfügbarkeit prüfen

Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes

BioMed research international, 2015-01, Vol.2015, p.341723-11

2015

Link zum Volltext

Verfügbarkeit prüfen

A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer

PloS one, 2015-12, Vol.10 (12), p.e0144126

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study

Gynecologic oncology, 2011-10, Vol.123 (1), p.19-26

2011

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

Molecular cancer therapeutics, 2015-11, Vol.14 (11), p.2569-2575

2015

Link zum Volltext

Verfügbarkeit prüfen

Metformin as a Therapeutic Target in Endometrial Cancers

Frontiers in oncology, 2018-08, Vol.8, p.341-341

2018

Link zum Volltext

Verfügbarkeit prüfen

Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)

Clinical cancer research, 2020-11, Vol.26 (21), p.5621-5630

2020

Link zum Volltext

Verfügbarkeit prüfen

RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model

Clinical cancer research, 2007-07, Vol.13 (14), p.4261-4270

2007

Link zum Volltext

Verfügbarkeit prüfen

mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary

Clinical cancer research, 2009-09, Vol.15 (17), p.5404-5413

2009

Link zum Volltext

Verfügbarkeit prüfen

Novel Approaches in Advancing the Treatment of Epithelial Ovarian Cancer: The Role of Angiogenesis Inhibition

Journal of clinical oncology, 2007-07, Vol.25 (20), p.2894-2901

2007

Link zum Volltext

Verfügbarkeit prüfen

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

Gynecologic oncology, 2012-11, Vol.127 (2), p.345-350

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

Gynecologic oncology, 2012-10, Vol.127 (1), p.63-69

2012

Link zum Volltext

Verfügbarkeit prüfen

Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer

JAMA oncology, 2020-01, Vol.6 (1), p.92

2020

Link zum Volltext

Verfügbarkeit prüfen

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study

Gynecologic oncology, 2019-12, Vol.155 (3), p.420-428

2019

Link zum Volltext

Verfügbarkeit prüfen

Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions

Seminars in oncology, 2009-04, Vol.36 (2), p.112-125

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study

Gynecologic oncology, 2011-05, Vol.121 (2), p.303-308

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study

Clinical cancer research, 2005-08, Vol.11 (15), p.5539-5548

2005

Link zum Volltext

Verfügbarkeit prüfen

A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer

Gynecologic oncology, 2011-05, Vol.121 (2), p.273-279

2011

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic oncology, 2017-11, Vol.147 (2), p.283-290

2017

Link zum Volltext

Verfügbarkeit prüfen

Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary

Molecular cancer therapeutics, 2013-07, Vol.12 (7), p.1367-1377

2013

Link zum Volltext

Verfügbarkeit prüfen

Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status

Journal of clinical oncology, 2006-09, Vol.24 (26), p.4324-4332

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 158

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(155)
Mit Volltextzugriff
(137)

Publikationsform

Artikel
(158)

Sprache

Englisch
(158)
Japanisch
(18)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Platinum Resistance: The Role of DNA Repair Pathways

Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

Metformin as a Therapeutic Target in Endometrial Cancers

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)

RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model

mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary

Novel Approaches in Advancing the Treatment of Epithelial Ovarian Cancer: The Role of Angiogenesis Inhibition

Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study

Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions

Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study

Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study

A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer

Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary

Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status

Suchergebnisse filtern